Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. / Kronborg, Thit M.; Schierwagen, Robert; Trošt, Kajetan; Gao, Qian; Moritz, Thomas; Bendtsen, Flemming; Gantzel, Rasmus H.; Andersen, Mette L.; Teisner, Ane S.; Grønbæk, Henning; Hobolth, Lise; Møller, Søren; Trebicka, Jonel; Kimer, Nina.
In: Hepatology Communications, Vol. 7, No. 12, e0332, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial
AU - Kronborg, Thit M.
AU - Schierwagen, Robert
AU - Trošt, Kajetan
AU - Gao, Qian
AU - Moritz, Thomas
AU - Bendtsen, Flemming
AU - Gantzel, Rasmus H.
AU - Andersen, Mette L.
AU - Teisner, Ane S.
AU - Grønbæk, Henning
AU - Hobolth, Lise
AU - Møller, Søren
AU - Trebicka, Jonel
AU - Kimer, Nina
N1 - Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
PY - 2023
Y1 - 2023
N2 - BACKGROUND: Patients with cirrhosis and portal hypertension face a high risk of complications. Besides their anti-inflammatory and antifibrotic effects, statins may reduce portal pressure and thus the risk of complications and mortality. We aimed to investigate the effects of atorvastatin on hospital admissions, mortality, inflammation, and lipidomics in cirrhosis with portal hypertension.METHODS: We performed a double-blinded, randomized, placebo-controlled clinical trial among patients with cirrhosis and portal hypertension. Atorvastatin (10-20 mg/d) was administered for 6 months. We measured splanchnic hemodynamics, analyzed inflammatory markers, and performed lipidomics at baseline and after 6 months.RESULTS: Seventy-eight patients were randomized, with 38 patients allocated to atorvastatin and 40 patients to placebo. Fifty-nine patients completed 6 months of intervention. Comparisons between changes in each group were calculated. Liver-related complications and mortality were similar between the groups. The HVPG and Model for End-stage Liver Disease score did not change between groups (p=0.95 and 0.87, respectively). Atorvastatin decreased 3 of 42 inflammatory markers, CD62-L-selectin, matrix metalloproteinases-2, and TNF-α (p-values: 0.005, 0.011, and 0.023, respectively), while lipidomics was not significantly changed.CONCLUSIONS: In patients with cirrhosis, atorvastatin was safe to use, but did not reduce mortality, the risk of liver-related complications, or the HVPG. Atorvastatin induced minor anti-inflammatory effects and minor effects on lipids during a 6-month treatment period.
AB - BACKGROUND: Patients with cirrhosis and portal hypertension face a high risk of complications. Besides their anti-inflammatory and antifibrotic effects, statins may reduce portal pressure and thus the risk of complications and mortality. We aimed to investigate the effects of atorvastatin on hospital admissions, mortality, inflammation, and lipidomics in cirrhosis with portal hypertension.METHODS: We performed a double-blinded, randomized, placebo-controlled clinical trial among patients with cirrhosis and portal hypertension. Atorvastatin (10-20 mg/d) was administered for 6 months. We measured splanchnic hemodynamics, analyzed inflammatory markers, and performed lipidomics at baseline and after 6 months.RESULTS: Seventy-eight patients were randomized, with 38 patients allocated to atorvastatin and 40 patients to placebo. Fifty-nine patients completed 6 months of intervention. Comparisons between changes in each group were calculated. Liver-related complications and mortality were similar between the groups. The HVPG and Model for End-stage Liver Disease score did not change between groups (p=0.95 and 0.87, respectively). Atorvastatin decreased 3 of 42 inflammatory markers, CD62-L-selectin, matrix metalloproteinases-2, and TNF-α (p-values: 0.005, 0.011, and 0.023, respectively), while lipidomics was not significantly changed.CONCLUSIONS: In patients with cirrhosis, atorvastatin was safe to use, but did not reduce mortality, the risk of liver-related complications, or the HVPG. Atorvastatin induced minor anti-inflammatory effects and minor effects on lipids during a 6-month treatment period.
KW - Humans
KW - Atorvastatin/therapeutic use
KW - End Stage Liver Disease
KW - Severity of Illness Index
KW - Liver Cirrhosis/complications
KW - Hypertension, Portal/etiology
KW - Anti-Inflammatory Agents
U2 - 10.1097/HC9.0000000000000332
DO - 10.1097/HC9.0000000000000332
M3 - Journal article
C2 - 38051553
VL - 7
JO - Hepatology Communications
JF - Hepatology Communications
SN - 2471-254X
IS - 12
M1 - e0332
ER -
ID: 379594474